Therapeutic Product Immunogenicity Community

 View Only
  • 1.  AI Immunogenicity models

    Community Leadership
    Posted 05-09-2023 12:35

    Hi All,

    With the current excitement around AI and machine learning I wanted to see what people think the impact of these technologies on the in silico immunogenicity prediction most of us are using.

    Some interesting papers have been published recently re the development of these deep learning models that I think can be utilized to assess immunogenicity risk of biotherapeutics.

    What do people think of these models? 

    Should we organize a webinar or workshop around this so we can discuss and learn more? 

    DeepImmuno : DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity
    TCR prediction: Can we predict T cell specificity with digital biology and machine learning? - Nature Reviews Immunology

    Nature remove preview
    Can we predict T cell specificity with digital biology and machine learning? - Nature Reviews Immunology
    Koohy and co-workers discuss how we must turn to machine-learning approaches to define the antigen specificity of the many millions of possible T cell receptors. They review the models and methods currently being used to predict cognate antigens for orphan T cell receptors.
    View this on Nature >




    OUP Academic remove preview
    DeepImmuno: deep learning-empowered prediction and generation of immunogenic peptides for T-cell immunity
    Cytolytic T-cells play an essential role in the adaptive immune system by seeking out, binding and killing cells that present foreign antigens on their surface. An improved understanding of T-cell immunity will greatly aid in the development of new cancer immunotherapies and vaccines for life-threatening pathogens.
    View this on OUP Academic >


     



    ------------------------------
    Jochem Gokemeijer
    Senior Director
    Bristol-Myer Squibb R&D CO
    Cambridge MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------


  • 2.  RE: AI Immunogenicity models

    Community Leadership
    Posted 05-10-2023 08:03

    The Bioanalytical Community has started a focus group on AI/Machine Learning.  @Roy Helmy at Merck is leading the team and I'd encourage you to collaborate with him and that group on this topic as we all try to figure out how AI is going to impact our pharmaceutical research in the future.



    ------------------------------
    Chad Briscoe PhD
    VP of Global Bioanalytical Labs
    Celerion
    Lincoln NE
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 3.  RE: AI Immunogenicity models

    Community Leadership
    Posted 05-10-2023 13:48

    That is actually a very good point: likely many different aspects of pharmaceutical development can and will be impacted by AI/ML. Maybe we should consider broader scope........ 



    ------------------------------
    Jochem Gokemeijer
    Senior Director
    Bristol-Myer Squibb R&D CO
    Cambridge MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 4.  RE: AI Immunogenicity models

    AAPS Staff
    Posted 05-11-2023 07:30

    I would love to hear the group's thoughts on the just-published FDA discussion papers regarding AI. Can AAPS contribute to the regulator dialog here?
    Cheers,
    Tina



    ------------------------------
    Tina Morris Ph.D.
    Executive Director
    AAPS
    Arlington VA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 5.  RE: AI Immunogenicity models

    Posted 05-10-2023 08:27

    Hi Jochem,
    I think this is a great idea! I would love to be involved in these forward looking discussions.
    Thanks for the papers.
    Uma.



    ------------------------------
    Uma Kavita
    Translational Immunology and Bioanalysis Leader
    Spark Therapeutics
    Philadelphia PA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------



  • 6.  RE: AI Immunogenicity models

    Posted 06-05-2023 18:34

    Jochem,

    Late to replying on this. This is a topic we think about alot, so would be excited to participate in any webinars or workshops on the topic. If we are thinking preclinical risk assessment, could be a great future topic/initiative for IRAM to cover. 

    Dan 



    ------------------------------
    Daniel Leventhal
    Associate Director
    Generate Biomedicines
    Somerville MA
    [email protected]

    Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
    ------------------------------